Developing novel medicines to tackle challenging health conditions is an extremely costly and inefficient process. For the last three decades, the timeline and cost of developing new drugs has been stagnant. In other words, the pharma industry has a productivity problem.
In 2019, TXI was approached by a Fortune 100 biopharma company with a huge vision: Double R&D productivity over five years by tapping existing data to create a centralized knowledge platform for their 14,000+ scientists to do hypothesis generation and exploration.
The big question: How do we tackle such an ambitious goal?